PerkinElmer Receives FDA Emergency Use Authorization for Respiratory SARS-CoV-2 Panel
RT-PCR test detects and differentiates SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 7, 2021– PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 assay. Qualified laboratories can immediately begin using this... Read more